Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice

Vaccine

Volumn 23, Issue 2, 2004, Pages 258-266

  Fifis, Theodora ^a   Mottram, Patricia ^a   Bogdanoska, Violeta ^a   Hanley, Jennifer ^a   Plebanski, Magdalena ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

Peptides; Tumours; Vaccine

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; GLUTAMYLGLUTAMINYLLEUCYLGLUTAMYLSERYLISOLEUCYLISOLEUCYLASPARAGINYL PHENYLALANYLGLUTAMYLLYSYLLEUCYLTHREONYLGLUTAMYLTRYPTOPHYLTHREONINE; LYSYLISOLEUCYLSERYLGLUTAMINYLALANYLVALYLHISTIDYLALANYLALANYLHISTIDYLALANYL GLUTAMYLISOLEUCYLASPARAGINYLGLUTAMYLALANYLGLYCYLARGINYLGLUTAMYLVALINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NANOBEAD; NANOPARTICLE; OVALBUMIN; PEPTIDE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; EPITOPES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; MICE; MICE, INBRED C57BL; NANOTECHNOLOGY; PEPTIDES; T-LYMPHOCYTES; VACCINES, CONJUGATE; VACCINES, SYNTHETIC;

EID: 8644226232     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.05.022     Document Type: Article

References (35)

1. D.T. O'Hagan Recent developments in vaccine delivery systems Curr. Drug Targets Infect. Disord. 1 3 2001 273 286
2. A. Ninomiya, K. Ogasawara, K. Kajino, A. Takada, and H. Kida Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice Vaccine 20 25-26 2002 3123 3129
3. J.T. Tan, J.K. Whitmire, and K. Murali-Krishna 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination J. Immunol. 164 5 2000 2320 2325
4. G. Parmiani, C. Castelli, and P. Dalerba Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst. 94 11 2002 805 818
5. J.L. Whitton, N. Sheng, M.B. Oldstone, and T.A. McKee A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge J. Virol. 67 1 1993 348 352
6. A. Vitiello, A. Sette, and L. Yuan Comparison of cytotoxic T lymphocyte responses induced by peptide or DNA immunization: implications on immunogenicity and immunodominance Eur. J. Immunol. 27 3 1997 671 678
7. R. Schirmbeck, and J. Reimann Alternative processing of endogenous or exogenous antigens extends the immunogenic, H-2 class I-restricted peptide repertoire Mol. Immunol. 39 3-4 2002 249 259
8. N. Romani, S. Koide, and M. Crowley Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells J. Exp. Med. 169 3 1989 1169 1178
9. A.Y. Huang, P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens Science 264 5161 1994 961 965
10. P.K. Srivastava, A. Menoret, S. Basu, R.J. Binder, and K.L. McQuade Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world Immunity 8 6 1998 657 665
11. M. Kovacsovics-Bankowski, K. Clark, B. Benacerraf, and K.L. Rock Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages Proc. Natl. Acad. Sci. U.S.A. 90 11 1993 4942 4946
12. A.W. Heath Cytokines as immunological adjuvants Pharm. Biotechnol. 6 1995 645 658
13. E. Davila, and E. Celis Repeated administration of cytosine- phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity J. Immunol. 165 1 2000 539 547
14. R.M. Vabulas, H. Pircher, G.B. Lipford, H. Hacker, and H. Wagner CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses J. Immunol. 164 5 2000 2372 2378
15. M. Cella, M. Salio, Y. Sakakibara, H. Langen, I. Julkunen, and A. Lanzavecchia Maturation, activation, and protection of dendritic cells induced by double-stranded RNA J. Exp. Med. 189 5 1999 821 829
16. G. Ada Vaccines and vaccination N. Engl. J. Med. 345 14 2001 1042 1053
17. J.T. Harty, A.R. Tvinnereim, and D.W. White CD8+ T cell effector mechanisms in resistance to infection Annu. Rev. Immunol. 18 2000 275 308
18. B. Faiola, C. Doyle, E. Gilboa, and S. Nair Influence of CD4 T cells and the source of major histocompatibility complex class II-restricted peptides on cytotoxic T-cell priming by dendritic cells Immunology 105 1 2002 47 55
19. A.L. Marzo, R.A. Lake, B.W. Robinson, and B. Scott T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors Cancer Res. 59 5 1999 1071 1079
20. K. Hung, R. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll, and H. Levitsky The central role of CD4(+) T cells in the antitumor immune response J. Exp. Med. 188 12 1998 2357 2368
21. J.C. Sun, and M.J. Bevan Defective CD8 T cell memory following acute infection without CD4 T cell help Science 300 5617 2003 339 342
22. B. Wang, C.C. Norbury, R. Greenwood, J.R. Bennink, J.W. Yewdell, and J.A. Frelinger Multiple paths for activation of naive CD8+ T cells: CD4-independent help J. Immunol. 167 3 2001 1283 1289
23. C. Fayolle, U.M. Abdel-Motal, L. Berg, E. Deriaud, M. Jondal, and C. Leclerc Induction of cytotoxic T-cell response by optimal-length peptides does not require CD4+ T-cell help Immunology 89 1 1996 41 45
24. C. Fayolle, P. Sebo, D. Ladant, A. Ullmann, and C. Leclerc In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T cell epitopes J. Immunol. 156 12 1996 4697 4706
25. M. Plebanski, S.C. Gilbert, and J. Schneider Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use Eur. J. Immunol. 28 12 1998 4345 4355
26. M.W. Moore, F.R. Carbone, and M.J. Bevan Introduction of soluble protein into the class I pathway of antigen processing and presentation Cell 54 6 1988 777 785
27. A. Porgador, J.W. Yewdell, Y. Deng, J.R. Bennink, and R.N. Germain Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody Immunity 6 6 1997 715 726
28. P. Aichele, K. Brduscha-Riem, R.M. Zinkernagel, H. Hengartner, and H. Pircher T cell priming versus T cell tolerance induced by synthetic peptides J. Exp. Med. 182 1 1995 261 266
29. S. Zwaveling, S.H. Van der Burg, A.G. Menon, C.J. Melief, and R. Offringa Immunotherapy of cancer through targeting of the p53 tumor antigen Arch. Immunol. Ther. Exp. (Warsz) 50 5 2002 297 305
30. J.A. Keene, and J. Forman Helper activity is required for the in vivo generation of cytotoxic T lymphocytes J. Exp. Med. 155 3 1982 768 782
31. S.R. Bennett, F.R. Carbone, F. Karamalis, R.A. Flavell, J.F. Miller, and W.R. Heath Help for cytotoxic-T-cell responses is mediated by CD40 signalling Nature 393 6684 1998 478 480
32. J.P. Ridge, F. Di Rosa, and P. Matzinger A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell Nature 393 6684 1998 474 478
33. S.P. Schoenberger, R.E. Toes, E.I. van der Voort, R. Offringa, and C.J. Melief T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions Nature 393 6684 1998 480 483
34. A. Viola, and A. Lanzavecchia T cell activation determined by T cell receptor number and tunable thresholds Science 273 5271 1996 104 106
35. H. Renz, K. Bradley, G.L. Larsen, C. McCall, and E.W. Gelfand Comparison of the allergenicity of ovalbumin and ovalbumin peptide 323-339 Differential expansion of V beta-expressing T cell populations J. Immunol. 151 12 1993 7206 7213